JNJ Sees FDA Approval for IMAAVY Amid Ongoing Talc Litigation

Johnson & Johnson (JNJ) has received FDA approval for IMAAVY to treat warm autoimmune hemolytic anemia in patients aged 12 and older. This comes on the heels of a Louisiana jury's verdict, which found the company partly liable in a talc-related mesothelioma case, assigning it over US$1.20 million of a US$10.00 million verdict.

The combination of expanding its rare disease portfolio with IMAAVY and ongoing talc litigation underscores how Johnson & Johnson's innovation efforts continue alongside persistent legal exposure.

Analysts project $120.5 billion in revenue and $28.6 billion in earnings for Johnson & Johnson by 2029, requiring 7.2% yearly revenue growth and a $7.6 billion earnings increase from $21.0 billion today.